个人简介
www.优德88.cpm 医学部基础医学与生物科学学院，教授，博导。2008年博士毕业；在加拿大玛格丽特公主癌症中心从事博士后研究工作，合作导师为研究中心副院长、UHN副总裁、加拿大健康科学院院士、国际著名的癌症疫苗研发与产业转化专家Christopher J. Paige教授。主要研究方向为：肿瘤免疫、mRNA疫苗、细胞治疗。本人近年来，以第一和通讯身份在发表肿瘤免疫相关的SCI论文10余篇，作为第一发明人获得授权的肿瘤疫苗发明专利2项。主持国家自然科学基金两项、江苏省高校自然科学基金、苏州市自然科学基金横向项目多项。担任国家自然科学基金评审专家，也是多本肿瘤免疫顶级杂志的特约审稿人包括Journal for Immunotherapy of cancer、leukemia、Cancer Letters、Journal of Immunology、Cancer Science、Scientific reports等杂志。
肿瘤免疫、mRNA疫苗
致力于通过肿瘤疫苗、溶瘤病毒等免疫治疗方法的研究，探索肿瘤进程与免疫系统的相互作用。
承担本科生的教学课程：《免疫学》、《医学免疫学》、《Medical Immunology》、《细胞工程》、《基因工程原理与技术》。
承担研究生的教学课程：《细胞与分子免疫学》
1.XuX,GanM,GeY,YiC,FengT,LiuM,WuC,ChenX,ZhangW*,ZhaoL*,ZouJ*. Multifaceted glycoadjuvant@AuNPs inhibits tumor metastasis through promoting T cell activation and remodeling tumor microenvironment. J Nanobiotechnology. 2021. 19(1): 376.(Corresponding author)
2. Xu X, Yi C, Yang X, Xu J, Sun Q, Liu Y,Zhao L. Tumor Cells Modified with Newcastle Disease Virus Expressing IL-24 as a Cancer Vaccine.Mol Ther Oncolytics. 2019. 14:213-221.(Corresponding author)
3. XuXiaojing, Jin Ziqi, Liu Yonghao, Gong Huanle, Sun Qing, Zhang Weidong,Zhao Lixiang*.Carbohydrate-based adjuvants activate tumor-specific Th1 and CD8+ T-cell responses and reduce the immunosuppressive activity of MDSCs.Cancer Letters. 2019. 440: 94~105.(Corresponding author)
4.Mei Yu,Zhao Lixiang#, Yonghao Liu,et al.Combining DNA Vaccine and AIDA-1 in Attenuated Salmonella Activates Tumor-Specific CD4(+) and CD8(+) T-cell Responses.Cancer Immunology Research.2017. 5(6):503-514.(Equal contributor)
5.Xu Xiaojing,Mei Yu,ZhaoLixiang*.Newcastle disease virus co-expressing interleukin 7 and interleukin 15 modified tumor cells as a vaccine for cancer immunotherapy.Cancer Science.2018.109(2): 279. (Corresponding author)
6.Zhao Lixiang,Mei Yu, Sun Qing,et al.Autologous tumor vaccine modified with recombinant new castle disease virus expressing IL-7 promotes antitumor immune response.The Journal of Immunology.2014.193(2): 735-745.
7. Xu Xiaojing, Sun Qing, Yu Xiao,ZhaoLixiang*.Rescue of nonlytic Newcastle Disease Virus (NDV) expressing IL-15 for cancer immunotherapy.Virus Research.2017. 233:35-41.
8. Xu Xiaojing, Chen Xiang, Gao Song,ZhaoLixiang*. Pathogenicity of FtsK mutant of avian pathogenicEscherichia coli2016. 60(1): 13~18. (Corresponding author）
9. Sun Qing#,Zhao Lixiang#, SongQingqing, et al.Hybrid- and complex-type N-glycans are notessential forNewcastle disease virus infection and fusion of host cells.Glycobiology.2012.(Equal contributor)
10. Zhao L,Liu H. Newcastle disease virus: a promising agent for tumor immunotherapy.Clin Exp Pharmacol Physiol.2012; 39(8): 725-30.
11. Zhao L,GaoS,HuanH,Xu X,Zhu X,Yang W,Gao Q,Liu X.Comparison of virulence factors and expression of specific genes between uropathogenicEscherichia coliand avian pathogenicE. coliin a murine urinary tract infection model and a chicken challenge model.Microbiology. 2009; 155: 1634-1644.
发明专利
1.赵李祥，梅雨，刘海燕。以减毒沙门氏菌为载体的口服肿瘤疫苗的制备及其应用。专利号：CN201310600070.6 （授权时间：2015年）
2.赵李祥，刘海燕，文丽君。一种重组新城疫病毒修饰的自体肿瘤疫苗的制备及其应用。专利号：CN201110188380.2（授权时间：2013年）
个人简介
www.优德88.cpm 医学部基础医学与生物科学学院，教授，博导。2008年博士毕业；在加拿大玛格丽特公主癌症中心从事博士后研究工作，合作导师为研究中心副院长、UHN副总裁、加拿大健康科学院院士、国际著名的癌症疫苗研发与产业转化专家Christopher J. Paige教授。主要研究方向为：肿瘤免疫、mRNA疫苗、细胞治疗。本人近年来，以第一和通讯身份在发表肿瘤免疫相关的SCI论文10余篇，作为第一发明人获得授权的肿瘤疫苗发明专利2项。主持国家自然科学基金两项、江苏省高校自然科学基金、苏州市自然科学基金横向项目多项。担任国家自然科学基金评审专家，也是多本肿瘤免疫顶级杂志的特约审稿人包括Journal for Immunotherapy of cancer、leukemia、Cancer Letters、Journal of Immunology、Cancer Science、Scientific reports等杂志。
肿瘤免疫、mRNA疫苗
致力于通过肿瘤疫苗、溶瘤病毒等免疫治疗方法的研究，探索肿瘤进程与免疫系统的相互作用。
承担本科生的教学课程：《免疫学》、《医学免疫学》、《Medical Immunology》、《细胞工程》、《基因工程原理与技术》。
承担研究生的教学课程：《细胞与分子免疫学》
1.XuX,GanM,GeY,YiC,FengT,LiuM,WuC,ChenX,ZhangW*,ZhaoL*,ZouJ*. Multifaceted glycoadjuvant@AuNPs inhibits tumor metastasis through promoting T cell activation and remodeling tumor microenvironment. J Nanobiotechnology. 2021. 19(1): 376.(Corresponding author)
2. Xu X, Yi C, Yang X, Xu J, Sun Q, Liu Y,Zhao L. Tumor Cells Modified with Newcastle Disease Virus Expressing IL-24 as a Cancer Vaccine.Mol Ther Oncolytics. 2019. 14:213-221.(Corresponding author)
3. XuXiaojing, Jin Ziqi, Liu Yonghao, Gong Huanle, Sun Qing, Zhang Weidong,Zhao Lixiang*.Carbohydrate-based adjuvants activate tumor-specific Th1 and CD8+ T-cell responses and reduce the immunosuppressive activity of MDSCs.Cancer Letters. 2019. 440: 94~105.(Corresponding author)
4.Mei Yu,Zhao Lixiang#, Yonghao Liu,et al.Combining DNA Vaccine and AIDA-1 in Attenuated Salmonella Activates Tumor-Specific CD4(+) and CD8(+) T-cell Responses.Cancer Immunology Research.2017. 5(6):503-514.(Equal contributor)
5.Xu Xiaojing,Mei Yu,ZhaoLixiang*.Newcastle disease virus co-expressing interleukin 7 and interleukin 15 modified tumor cells as a vaccine for cancer immunotherapy.Cancer Science.2018.109(2): 279. (Corresponding author)
6.Zhao Lixiang,Mei Yu, Sun Qing,et al.Autologous tumor vaccine modified with recombinant new castle disease virus expressing IL-7 promotes antitumor immune response.The Journal of Immunology.2014.193(2): 735-745.
7. Xu Xiaojing, Sun Qing, Yu Xiao,ZhaoLixiang*.Rescue of nonlytic Newcastle Disease Virus (NDV) expressing IL-15 for cancer immunotherapy.Virus Research.2017. 233:35-41.
8. Xu Xiaojing, Chen Xiang, Gao Song,ZhaoLixiang*. Pathogenicity of FtsK mutant of avian pathogenicEscherichia coli2016. 60(1): 13~18. (Corresponding author）
9. Sun Qing#,Zhao Lixiang#, SongQingqing, et al.Hybrid- and complex-type N-glycans are notessential forNewcastle disease virus infection and fusion of host cells.Glycobiology.2012.(Equal contributor)
10. Zhao L,Liu H. Newcastle disease virus: a promising agent for tumor immunotherapy.Clin Exp Pharmacol Physiol.2012; 39(8): 725-30.
11. Zhao L,GaoS,HuanH,Xu X,Zhu X,Yang W,Gao Q,Liu X.Comparison of virulence factors and expression of specific genes between uropathogenicEscherichia coliand avian pathogenicE. coliin a murine urinary tract infection model and a chicken challenge model.Microbiology. 2009; 155: 1634-1644.
发明专利
1.赵李祥，梅雨，刘海燕。以减毒沙门氏菌为载体的口服肿瘤疫苗的制备及其应用。专利号：CN201310600070.6 （授权时间：2015年）
2.赵李祥，刘海燕，文丽君。一种重组新城疫病毒修饰的自体肿瘤疫苗的制备及其应用。专利号：CN201110188380.2（授权时间：2013年）